Viromed Medical AG Advances Development and Confirms Guidance

Viromed Medical AG has released its half-year report for 2026, highlighting advancements in product development and market strategy. The company focused on preclinical research and strategic sales partnerships, with significant progress in the development of PulmoPlas® and ViroCAP®. Notably, Viromed initiated OEM production for HELLMUT RUCK GmbH and secured a partnership with NEBU-TEC for PulmoPlas® veterinary applications.

Official approval under the EU Medical Device Regulation was achieved for ViroCAP® med, facilitating sales launch. Despite a net loss of €1.1 million largely due to study and launch expenses, revenues rose slightly to €2.5 million. Equity grew by 43.9% to €9.5 million, supported by a loan from Perbamed Invest GmbH. The company anticipates significant financial gains by year-end, reaffirming its full-year guidance.